ArticleNPJ Parkinson's disease2026
Multi-omic insight into the molecular mechanism of cuproptosis-related genes in the pathogenesis of Parkinson's disease.
Article in NPJ Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cuproptosis has been linked to Parkinson's disease (PD), but underlying genetic mechanisms remain unclear. We integrated multi-omic QTL data (methylation, gene expression, protein) with GWAS data of PD (discovery: GWAS Catalog; replication: UK Biobank/FinnGen/IEU). Integrated summary-data Mendelian randomization (SMR) with colocalization analyses revealed regulatory relationships involving 4 candidate genes (ISCA1, PDE6B, PTGES, and CERS2). Replication analyses demonstrated consistent CERS2/PDE6B methylation effects across cohorts. Experimental validation in MPTP-treated mice demonstrated that the copper chelator tetrathiomolybdate (TTM) robustly rescued motor deficits and prevented dopaminergic neurodegeneration. Mechanistically, TTM reversed core features of cuproptosis, including striatal copper accumulation and the destabilization of lipoylated TCA cycle proteins. TTM also normalized the expression of all four candidate genes, confirming a copper-dependent regulatory axis predicted by our SMR analysis. This study provides a functional link between cuproptosis-related genes and PD pathogenesis, highlighting copper dyshomeostasis as a key pathogenic driver and a potential therapeutic target.
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.